Psychedelics Archives | Page 2 of 32

Wall Street Is About to Steal Psychedelics From the People Who Need Them

The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap, zero revenue. MindMed: up to $2 billion, […]

Harry Styles has openly linked the recording of his 2019 album Fine Line to mushrooms, sunshine and Rick Rubin’s Malibu lawn. A […]

Integration after a psychedelic experience is serious business. Or at least, that’s what we’ve been taught. Serious as in: dig deep into […]

Jamaica has always had ganja. Now it has the mushrooms too — and a growing number of retreats are finally putting them […]

Voter support for psychedelic research, therapy and prescription access all surged. Decrim didn’t move. A new Berkeley survey says it out loud. […]

President Trump signed an executive order on April 18 directing the FDA to fast-track review of psychedelic therapies and committing $50 million […]

Psychedelic legislation is moving through more state capitols simultaneously than at any point in history. The question is not whether reform is […]

One of the biggest myths about drugs is that their use is new, purely recreational, or a way to escape reality. “In […]

The DoubleBlind Guide to Psychedelics: A Road Map to Tripping, Microdosing, and Beyond is available for pre-order now and hits shelves April […]

It’s difficult to admit this—especially to the readers of High Times—but for most of my life, I flat-out hated the hippies. That’s […]